Our Services
Medical Information
Helpful Resources
Published on: 1/30/2026
Farxiga can meaningfully help older adults by improving blood sugar with low hypoglycemia risk, reducing heart failure hospitalizations, and slowing kidney disease, but it can also increase dehydration, UTIs, and dizziness from lower blood pressure. There are several factors to consider; see below for details that could change your next steps. Staying well hydrated, reporting symptoms early, and reviewing other medications can reduce risks, especially if you use diuretics, have recurrent UTIs, fall risk, or advanced kidney disease. For personalized watch‑outs, red flags, and when to call your doctor, see the complete answer below.
If you are over 65 and have been prescribed farxiga (dapagliflozin), it’s normal to want a clear, balanced explanation of what it can help with—and what to watch for. Farxiga is widely used and well-studied, including in older adults, but age can change how your body responds to medications. Below is a practical, plain‑language guide to the benefits and risks of farxiga, with special attention to dehydration, urinary tract infections (UTIs), and dizziness.
Farxiga is a prescription medication in a class called SGLT2 inhibitors. It works by helping your kidneys remove excess sugar through the urine.
Doctors prescribe farxiga for several conditions, including:
Because these conditions are more common after age 65, farxiga is frequently used in older adults.
Large clinical studies and real‑world use show that farxiga offers meaningful benefits, even later in life.
Farxiga lowers blood sugar without relying on insulin.
Why this matters for older adults:
Farxiga reduces the risk of hospitalization for heart failure and can improve symptoms like shortness of breath and fatigue.
Key advantages:
Farxiga slows the progression of chronic kidney disease.
For those over 65:
Farxiga may cause mild weight loss and slightly lower blood pressure.
While farxiga has real benefits, certain side effects deserve extra attention after age 65.
Farxiga makes you urinate more to remove sugar from the body. This can also cause fluid loss.
Older adults are more vulnerable because:
If you’re unsure whether your symptoms might be related to fluid loss, you may want to consider a free, online symptom check for Dehydration to help decide next steps.
Because farxiga increases sugar in the urine, it can create an environment where bacteria grow more easily.
Older adults may already be at higher risk due to:
Most UTIs linked to farxiga are mild and treatable, especially when caught early.
Farxiga can lower blood pressure slightly. In older adults, this may cause:
This is more likely if you:
Falls are not an inevitable part of aging, and medication adjustments can often reduce this risk.
Less common but important side effects include:
Your healthcare provider will typically monitor kidney function and overall health through regular blood tests.
You may need closer monitoring or a different treatment if you:
This does not mean farxiga is unsafe—but it does mean personalized care is essential.
Before starting or continuing farxiga, consider discussing:
Always speak to a doctor right away if you experience symptoms that feel severe, sudden, or life‑threatening, such as fainting, confusion, high fever, or signs of a serious infection.
Farxiga offers real, evidence‑based benefits for blood sugar control, heart failure, and kidney protection—even in older adults. For many people over 65, these benefits outweigh the risks when the medication is used thoughtfully and monitored closely.
At the same time, dehydration, UTIs, and dizziness are not side effects to ignore. The good news is that most risks can be reduced with:
If something doesn’t feel right, trust your instincts and speak to a doctor. Medications work best when they fit your body, your health goals, and your stage of life.
With the right guidance, farxiga can be a helpful part of staying healthier and more independent as you age.
(References)
* Li D, Li H, Li S, Lin H, Jia W, Wang Z, Gu R. Dapagliflozin in elderly patients with type 2 diabetes: a systematic review and meta-analysis. J Diabetes Complications. 2019 May;33(5):372-381. doi: 10.1016/j.jdiacomp.2019.01.011. Epub 2019 Jan 21. PMID: 30678683.
* Alatawi Y, Alnami F, Alenzi F, Alenzi A, Alsogair M. Safety of SGLT2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus: A Narrative Review. Cureus. 2022 Oct 11;14(10):e30198. doi: 10.7759/cureus.30198. PMID: 36364132; PMCID: PMC9642699.
* Tella SH, Chung S, Gupte R, Vella A, Zaccardi F. Adverse events of SGLT2 inhibitors in older adults with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2020 Aug;22(8):1292-1304. doi: 10.1111/dom.14039. Epub 2020 May 19. PMID: 32415664.
* Cho NH, Vella A, Cho YK, Pan C, Han P, Li Y, Rhee EJ, Tan H, Yang W. Real-world effectiveness and safety of dapagliflozin in older patients with type 2 diabetes mellitus from the Asia-Pacific region: Results from the Asia-Pacific Diabetes and Cardiovascular (ADVICE) Registry. J Diabetes Investig. 2021 Jul;12(7):1233-1243. doi: 10.1111/jdi.13508. Epub 2021 Mar 22. PMID: 33918076; PMCID: PMC8255953.
* Mascolo A, Sessa M, Faillace P, Vitale C, Capuano A. Cardiorenal Benefits of SGLT2 Inhibitors in the Elderly: A Narrative Review. J Cardiovasc Dev Dis. 2022 May 19;9(5):165. doi: 10.3390/jcdd9050165. PMID: 35626998; PMCID: PMC9144490.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.